Inhibitory action of reveromycin A on TGF-alpha-dependent growth of ovarian carcinoma BG-1 in vitro and in vivo.
H Takahashi, Y Yamashita, H Takaoka, J Nakamura, M Yoshihama, H Osada
Index: Oncol. Res. 9(1) , 7-11, (1997)
Full Text: HTML
Abstract
The antitumor effect of reveromycin A (RM-A), an inhibitor of EGF-dependent cell proliferation on murine and human tumor cell lines, was examined in vitro and in vivo, RM-A showed little antitumor effect against three murine tumors tested, but showed strong antitumor effect (a minimum treated/control ratio of 36%) against a human ovarian carcinoma BG-1, which is known to be a transforming growth factor alpha (TGF-alpha)-secreting and estrogen receptor-expressing cell line. In BG-1 cells, RM-A inhibited the cell proliferation induced by TGF-alpha at the concentration range 30-300 nM, but did not inhibit the proliferation induced by 17 beta-estradiol (E2).RM-A is a possible new antitumor drug with a novel mechanism of action and may also be a useful tool for the analysis of epidermal growth factor receptor (EGFR)-mediated cell proliferation in tumor cells.
Related Compounds
Related Articles:
2003-05-01
[Curr. Med. Chem. 10(9) , 727-32, (2003)]
2009-11-01
[Cancer Sci. 100(11) , 1999-2005, (2009)]
2008-07-01
[Bioorg. Med. Chem. Lett. 18(13) , 3756-60, (2008)]
2008-04-01
[J. Pharmacol. Sci. 106(4) , 547-54, (2008)]
2013-04-01
[J. Antibiot. 66(4) , 247-50, (2013)]